Level	Gene	Alterations	Cancer Types	Drugs (for therapeutic implications only)
1	ALK	Fusions	Non-Small Cell Lung Cancer	Alectinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Brigatinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ceritinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Lorlatinib
1	BRAF	V600E	All Solid Tumors (excluding Colorectal Cancer)	Dabrafenib + Trametinib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Dacomitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Erlotinib, Erlotinib + Ramucirumab
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Gefitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Osimertinib
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Amivantamab
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Mobocertinib
1	EGFR	G719	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	L861Q	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	S768I	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib
1	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab Deruxtecan
1	KRAS	G12C	Non-Small Cell Lung Cancer	Adagrasib
1	KRAS	G12C	Non-Small Cell Lung Cancer	Sotorasib
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Capmatinib
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Tepotinib
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	Other Biomarkers	Tumor Mutational Burden-High	All Solid Tumors	Pembrolizumab
1	RET	Fusions	Non-Small Cell Lung Cancer	Pralsetinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib
R1	EGFR	Exon 20 in-frame insertions (excluding A763_Y764insFQEA)	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Afatinib
R1	EGFR	T790M	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Afatinib
R1	NTRK1	G595R	All Solid Tumors	Larotrectinib
R1	NTRK3	F617L	All Solid Tumors	Larotrectinib
R1	NTRK3	G623R	All Solid Tumors	Larotrectinib
R1	NTRK3	G696A	All Solid Tumors	Larotrectinib
2	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Erlotinib
2	EGFR	G719	Non-Small Cell Lung Cancer	Osimertinib
2	EGFR	L861Q	Non-Small Cell Lung Cancer	Osimertinib
2	EGFR	S768I	Non-Small Cell Lung Cancer	Osimertinib
2	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine
2	MET	Amplification	Non-Small Cell Lung Cancer	Capmatinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Crizotinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Tepotinib
2	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Crizotinib
2	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib
2	ROS1	Fusions	Non-Small Cell Lung Cancer	Ceritinib
2	ROS1	Fusions	Non-Small Cell Lung Cancer	Lorlatinib
3	ARAF	Oncogenic Mutations	Non-Small Cell Lung Cancer	Sorafenib
3	EGFR	E709_T710delinsD	Non-Small Cell Lung Cancer	Afatinib
3	EGFR	Exon 19 in-frame deletions, Exon 19 in-frame insertions, G719, L858R, L861Q, S768I	Non-Small Cell Lung Cancer	Patritumab Deruxtecan
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Erlotinib
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Gefitinib
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	CLN-081
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Poziotinib
3	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Neratinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab + Pertuzumab + Docetaxel
3	FGFR1	Amplification	Lung Squamous Cell Carcinoma	Debio1347, Infigratinib, Erdafitinib
3	MAP2K1	Oncogenic Mutations	Melanoma, Non-Small Cell Lung Cancer, Low-Grade Serous Ovarian Cancer	Trametinib, Cobimetinib
3	MET	Amplification	Non-Small Cell Lung Cancer	Telisotuzumab Vedotin
3	MET	Y1003	Non-Small Cell Lung Cancer	Tepotinib, Capmatinib, Crizotinib
3	NRG1	Fusions	All Solid Tumors	Zenocutuzumab
3	NRG1	Fusions	Non-Small Cell Lung Cancer	Seribantumab
3	NTRK1	Fusions	All Solid Tumors	Repotrectinib
3	NTRK2	Fusions	All Solid Tumors	Repotrectinib
3	NTRK3	Fusions	All Solid Tumors	Repotrectinib
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib
3	ROS1	Fusions	Non-Small Cell Lung Cancer	Repotrectinib
3	TP53	Y220C	All Solid Tumors	PC14586
4	ARID1A	Truncating Mutations	All Solid Tumors	PLX2853
4	ARID1A	Truncating Mutations	All Solid Tumors	Tazemetostat
4	BRAF	G464, G469A, G469R, G469V	All Solid Tumors	PLX8394
4	BRAF	K601	All Solid Tumors	PLX8394
4	BRAF	L597	All Solid Tumors	PLX8394
4	CCNE1	Amplification	All Solid Tumors	RP-6306, BLU-222
4	CDK12	Truncating Mutations	All Solid Tumors	Pembrolizumab, Nivolumab, Cemiplimab
4	CDKN2A	Oncogenic Mutations	All Solid Tumors	Palbociclib, Ribociclib, Abemaciclib
4	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	D761Y	Non-Small Cell Lung Cancer	Osimertinib
4	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Erlotinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Gefitinib
4	EGFR	L718V	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	L747P	Non-Small Cell Lung Cancer	Afatinib
4	FGFR1	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR2	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR3	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	KRAS	G12D	All Solid Tumors	RMC-6236
4	KRAS	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib, Binimetinib
4	MET	Fusions	All Solid Tumors	Crizotinib
4	MTOR	Oncogenic Mutations	All Solid Tumors	Everolimus, Temsirolimus
4	NF1	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib
4	PIK3CA	H1047R	All Solid Tumors (excluding Colorectal Cancer)	LOXO-783
4	PIK3CA	Oncogenic Mutations	All Solid Tumors	RLY-2608
4	PTEN	Oncogenic Mutations	All Solid Tumors	GSK2636771, AZD8186
4	STK11	Oncogenic Mutations	Non-Small Cell Lung Cancer	Bemcentinib + Pembrolizumab
R2	ALK	C1156Y	Non-Small Cell Lung Cancer	Crizotinib
R2	ALK	G1202R	Non-Small Cell Lung Cancer	Alectinib
R2	ALK	G1269A	Non-Small Cell Lung Cancer	Crizotinib
R2	ALK	I1171N	Non-Small Cell Lung Cancer	Alectinib
R2	ALK	L1196M	Non-Small Cell Lung Cancer	Crizotinib
R2	EGFR	C797G	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	C797S	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	D761Y	Non-Small Cell Lung Cancer	Gefitinib
R2	EGFR	G724S	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	L718V	Non-Small Cell Lung Cancer	Osimertinib
R2	MET	Amplification	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Osimertinib
R2	MET	D1228N	Non-Small Cell Lung Cancer	Crizotinib, Cabozantinib, Capmatinib
R2	MET	Y1230H	Non-Small Cell Lung Cancer	Crizotinib, Capmatinib
R2	NTRK1	G595R	All Solid Tumors	Entrectinib